With over 30 years of experience across 250+ therapeutic indications, Avance Clinical is renowned for delivering high-quality clinical trial data accepted by key global regulators, including the FDA, EMA, TGA, MHRA, MFDS, and PMDA. Taichung Veterans General Hospital has established itself as a center of excellence in oncology, rare diseases, and regenerative medicine, with state-of-the-art genetic and stem cell laboratories and a dedicated CAR-T therapy program, reinforcing its leadership in innovative clinical research.
Prof. Yun-Ching Fu, Dean of Taichung Veterans General Hospital, said, “Taichung Veterans General Hospital is committed to advancing global healthcare through cutting-edge research and clinical innovation. Our well-established early-phase unit and expertise in regenerative medicine provide a strong foundation for collaboration with Avance Clinical. By joining forces, we can accelerate clinical development and expand access to breakthrough treatments for patients worldwide.”
Avance Clinical CEO Yvonne Lungershausen emphasized the importance of Taiwan in the company’s broader clinical trial strategy.
“This agreement with Taichung Veterans General Hospital strengthens our ability to support biotechs looking to leverage Asia’s advanced clinical research ecosystem. Taiwan offers an exceptional regulatory environment, rapid study start-up timelines, and access to highly experienced investigators, making it a prime location for early-phase trials.”
“As biotechs transition from early-phase to later-phase trials, seamless patient recruitment and regulatory expertise become critical. Our expanded presence in Taiwan, alongside our established operations in South Korea, ensures biotechs benefit from a streamlined path to multi-regional trials, faster patient enrolment, and world-class trial data recognized by global regulatory agencies,” Lungershausen said.
This partnership further reinforces Avance Clinical’s Asia Advantage, a strategic initiative designed to provide biotech sponsors with accelerated clinical trial solutions across Australia, New Zealand, Taiwan, and South Korea, offering faster study start-up, regulatory flexibility, and high-quality data collection.
About Taichung Veterans General Hospital (TCVGH)
Founded in 1982, Taichung Veterans General Hospital (TCVGH) is a premier medical centre in Taiwan, renowned for its leadership in clinical research and specialized healthcare services. With over 1,600 beds and 6,000 employees, the hospital serves more than 8,500 outpatient visits daily. TCVGH is a recognized pioneer in smart hospital technology, early-phase clinical trials, and regenerative medicine, providing cutting-edge patient care and driving innovation in global drug development.
About Avance Clinical
Avance Clinical is a leading global CRO specializing in early to late-phase clinical trials for biotech companies. Headquartered in Australia, Avance Clinical delivers faster, more flexible, and high-quality clinical trial solutions with a strong focus on regulatory compliance and patient-centric research. With a global footprint spanning Australia, New Zealand, Asia, North America, and Europe, Avance Clinical offers comprehensive support from preclinical consulting to Phase I-III trials, ensuring biotech sponsors achieve efficient trial execution and regulatory success.
